Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price fell 2.8% on Friday . The stock traded as low as $6.82 and last traded at $6.90, with a volume of 134,734 shares traded. The stock had previously closed at $7.10.

Several brokerages recently weighed in on NEOS. BMO Capital Markets began coverage on shares of Neos Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $15.00 price target on the stock. Royal Bank Of Canada cut their price target on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating on the stock in a report on Tuesday, May 17th. Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. Finally, Zacks Investment Research downgraded shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $21.75.

The company has a 50 day moving average of $7.97 and a 200-day moving average of $9.33. The company’s market cap is $112.49 million.

Neos Therapeutics (NASDAQ:NEOS) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.49. The firm earned $1.49 million during the quarter, compared to analyst estimates of $1.48 million. Equities research analysts forecast that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.

In related news, CFO Richard I. Eisenstadt acquired 3,710 shares of the firm’s stock in a transaction dated Thursday, August 25th. The stock was acquired at an average price of $6.82 per share, for a total transaction of $25,302.20. Following the purchase, the chief financial officer now owns 3,710 shares of the company’s stock, valued at approximately $25,302.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Juergen Martens acquired 10,000 shares of the firm’s stock in a transaction dated Monday, June 13th. The stock was bought at an average price of $9.90 per share, with a total value of $99,000.00. Following the purchase, the insider now directly owns 10,000 shares in the company, valued at approximately $99,000. The disclosure for this purchase can be found here.

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.